Russell Investments Group Ltd. Has $2.28 Million Position in OraSure Technologies, Inc. $OSUR

Key Points

• Russell Investments Group Ltd. has increased its stake in OraSure Technologies by 111.1%, acquiring a total of 676,334 shares valued at approximately $2.28 million.
• Several hedge funds have also raised their positions in OraSure Technologies, with institutional investors now owning 93.50% of the company's stock.
• OraSure Technologies' stock has recently seen a price increase of 4.7% and is currently trading around $3.14, with a market cap of $229.65 million.

Russell Investments Group Ltd. grew its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 111.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 676,334 shares of the medical instruments supplier's stock after buying an additional 355,915 shares during the period. Russell Investments Group Ltd. owned approximately 0.87% of OraSure Technologies worth $2,279,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in OSUR. Private Management Group Inc. bought a new position in shares of OraSure Technologies during the 1st quarter valued at about $14,886,000. Gagnon Securities LLC bought a new position in shares of OraSure Technologies during the 1st quarter valued at about $3,619,000. D. E. Shaw & Co. Inc. lifted its holdings in shares of OraSure Technologies by 180.5% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,517,541 shares of the medical instruments supplier's stock valued at $5,478,000 after purchasing an additional 976,475 shares in the last quarter. Gagnon Advisors LLC bought a new position in shares of OraSure Technologies during the 1st quarter valued at about $2,687,000. Finally, Systematic Financial Management LP lifted its holdings in shares of OraSure Technologies by 33.7% during the 4th quarter. Systematic Financial Management LP now owns 1,673,609 shares of the medical instruments supplier's stock valued at $6,042,000 after purchasing an additional 421,497 shares in the last quarter. Institutional investors own 93.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on OSUR. Evercore ISI reiterated an "in-line" rating and set a $3.00 price objective on shares of OraSure Technologies in a report on Monday, May 19th. Wall Street Zen upgraded OraSure Technologies from a "sell" rating to a "hold" rating in a report on Saturday, May 17th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, OraSure Technologies presently has a consensus rating of "Hold" and a consensus price target of $3.00.

OraSure Technologies Stock Performance

OraSure Technologies stock traded up $0.02 during midday trading on Friday, reaching $3.31. The stock had a trading volume of 747,291 shares, compared to its average volume of 632,416. The stock has a market capitalization of $242.09 million, a P/E ratio of -4.94 and a beta of 0.27. OraSure Technologies, Inc. has a 1-year low of $2.36 and a 1-year high of $4.61. The firm's fifty day simple moving average is $3.07 and its 200-day simple moving average is $3.10.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.